View in Other Languages

Basilea Pharmaceutica AG

SWF:BSLN ISIN:CH0011432447

Basilea Pharmaceutica AG (SWF:BSLN) is a Switzerland-based research and development biopharmaceutical Company. The Company focuses its activities on the areas of antibacterial, antifungal and oncology agents to fight drug resistance and on the development of dermatology drugs. The Company's late-stage product portfolio comprises novel treatments for resistant bacterial infections, systemic fungal infections, and severe skin diseases. The Company's portfolio includes two commercialized drugs, alitretinoin and ceftobiprole, one investigational drug, isavuconazole, in phase III, as well as substantial early-state programs.

  

News

Asian Markets Overview of February 25

🕔2/25/2010 1:30:31 PM 12292

Asian markets mostly dropped on Wednesday. Resources shares across the region were hit by falling metals prices. Japan's Nikkei 225 fell 1.5 per cent, South Korea's Kospi shed 1.0 per cent and Hong Kong's Hang Seng Index lost 0.8 per cent. The markets also weighed down by U.S. consumer confidence and German business sentiment. But China's Shanghai Composite rebounded 1.3 per cent as monetary tightening worries eased.

Read Full Article

Basilea Pharmaceutica AG (VTX:BSLN) Ceftobiprole, A New Anti-mrsa Broad-spectrum Antibiotic, Receives Approval By Swissmedic

🕔11/13/2008 4:17:00 PM 4464

Basilea Pharmaceutica AG (VTX:BSLN) Basel, Switzerland, November 13, 2008 - Basilea Pharmaceutica Ltd. announces that ceftobiprole (Zevtera(TM)), the first-in-class anti-MRSA broad-spectrum cephalosporin, has obtained regulatory approval from Swissmedic for the treatment of complicated skin and soft tissue infections including diabetic foot infections.

Read Full Article

Basilea Pharmaceutica AG (SWF:BSLN) Basilea Presents Research Data At ICAAC/IDSA On Novel Antibiotic Addressing The Emerging Threat From Multi-resistant Gram-negative bacteria

🕔10/27/2008 5:17:00 PM 4329

Basilea Pharmaceutica AG (SWF:BSLN) Basel, Switzerland, October 27, 2008 - Multi-resistant Gram-negative bacteria are causing increasing concern around the world. Basilea's novel antibiotic BAL30072 demonstrates potent in-vitro activity against some of the most difficult to treat multi-resistant Gram-negative bacteria.

Read Full Article

Basilea Pharmaceutica AG (SWF:BSLN) Basilea's Toctino® (alitretinoin) Receives Marketing Authorization In France

🕔10/21/2008 4:17:00 PM 5126

Basilea Pharmaceutica AG (SWF:BSLN) Basel, Switzerland, October 21, 2008 - Basilea Pharmaceutica Ltd. announces that Toctino® (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been approved by the French Health Products Safety Agency (Agence Française de Sécurité Sanitaire des Produits de Santé [AFSSAPS]).

Read Full Article

Basilea Pharmaceutica AG (SWF:BSLN) Basilea Announces New Data To Be Presented On Ceftobiprole And Isavuconazole At ICAAC/IDSA

🕔10/20/2008 3:17:00 PM 3811

Basilea Pharmaceutica AG (SWF:BSLN) Basel, Switzerland, October 20, 2008 - New data on Basilea's late-stage anti-infectives ceftobiprole and isavuconazole will be presented at the upcoming joint meeting of the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the Infectious Disease Society of America (IDSA) in Washington DC.

Read Full Article

Basilea Pharmaceutica AG (SWF:BSLN) Basilea's Toctino® (alitretinoin) Receives Marketing Authorization In Finland

🕔10/15/2008 3:17:00 PM 4713

Basilea Pharmaceutica AG (SWF:BSLN) Basel, Switzerland, October 15, 2008 - Basilea Pharmaceutica Ltd. announces that Toctino® (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been approved by Finland's National Agency for Medicines (NAM).

Read Full Article

Basilea Pharmaceutica AG (SWF:BSLN) Basilea's Toctino® (alitretinoin) Receives Marketing Authorization In Germany

🕔10/6/2008 3:17:00 PM 2505

Basilea Pharmaceutica AG (SWF:BSLN) Basel, Switzerland, October 6, 2008 - Basilea Pharmaceutica Ltd. announces that Toctino® (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been approved by the German health authority "Bundesinstitut für Arzneimittel und Medizinprodukte" (BfArM).

Read Full Article

Basilea Pharmaceutica AG (SWF:BSLN) Basilea's Toctino® (alitretinoin) Receives Marketing Authorization In Denmark

🕔9/22/2008 3:17:00 PM 2500

Basilea Pharmaceutica AG (SWF:BSLN) Basel, Switzerland, September 22, 2008 - Basilea Pharmaceutica Ltd. announces that Toctino® (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been approved by the Danish Medicines Agency (DKMA).

Read Full Article

Basilea Pharmaceutica AG (SWF:BSLN) FDA Accepts For Review The Complete Response To Ceftobiprole NDA Approvable Letter

🕔9/15/2008 3:17:01 PM 2063

Basilea Pharmaceutica AG (SWF:BSLN) Basel, Switzerland, September 15, 2008 - Basilea Pharmaceutica Ltd. announces that the Food and Drug Administration (FDA) has accepted for review the Complete Response to the ceftobiprole New Drug Application (NDA) Approvable Letter.

Read Full Article

Basilea Pharmaceutica AG (SWF:BSLN) Basilea's Toctino® (alitretinoin) Receives First National Marketing Authorization In The UK

🕔9/8/2008 3:17:00 PM 2203

Basilea Pharmaceutica AG (SWF:BSLN) Basel, Switzerland, September 8, 2008 - Basilea Pharmaceutica Ltd. announces that Toctino® (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom.

Read Full Article
###

40,610 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 12) (Last 30 Days: 68) (Since Published: 8865) 

Company Data

    Principal Sector
  • Ag Biotechnology 
  • Principal Industry
  • Healthcare 
  • Homepage
  • www.basilea.com

Social Media